Sidewinder Therapeutics has announced the successful closure of a substantial $137 million Series B financing round, a significant development signaling…
Read More
Apnimed Secures Up to $150 Million in Credit Facility to Fuel Potential US Launch of Obstructive Sleep Apnea Therapy AD109
Boston, MA – – Apnimed, a clinical-stage biopharmaceutical company focused on developing novel therapies for sleep-related breathing disorders, has announced…
Read More
Eli Lilly’s Foundayo Secures FDA Approval, Challenging Novo Nordisk’s Oral Obesity Drug Dominance
The United States Food and Drug Administration (FDA) has granted approval to Eli Lilly and Company’s novel oral glucagon-like peptide-1…
Read More
Teva Pharmaceutical Secures FDA Approval for Ponlimsi Biosimilar to Prolia, Advances Xolair Biosimilar Applications in US and EU
Teva Pharmaceutical has announced a significant milestone in its biosimilar portfolio with the U.S. Food and Drug Administration (FDA) granting…
Read More
Novo Nordisk Secures FDA Approval for Awiqli, a Once-Weekly Basal Insulin for Adults with Type 2 Diabetes
The United States Food and Drug Administration (FDA) has granted approval to Novo Nordisk for Awiqli (insulin icodec-abae) injection 700…
Read More
Vitestro Secures $70 Million in Oversubscribed Series B to Accelerate Autonomous Phlebotomy Development and Global Commercialization
Utrecht, Netherlands – Vitestro, a pioneering medical robotics company, has successfully closed an oversubscribed Series B financing round, securing an…
Read More
Darzalex Secures Landmark European Approval for Self-Administration in Multiple Myeloma, Ushering in a New Era of Home-Based Cancer Care
Johnson & Johnson’s (J&J) groundbreaking cancer immunotherapy, Darzalex (daratumumab), has achieved a pivotal milestone in its European market penetration with…
Read More
Rocket Pharmaceuticals Secures Landmark FDA Approval for Kresladi, Ushering in a New Era for Ultra-Rare Immune Disease Treatment
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Rocket Pharmaceuticals’ Kresladi (marnetegragene autotemcel), a groundbreaking gene…
Read More
Sanofi Secures Global Rights to Kali Therapeutics’ Promising Tri-Specific Antibody KT501 for Autoimmune Diseases in a Landmark $1.23 Billion Deal
Sanofi has entered into an exclusive global license agreement with Kali Therapeutics, a significant move that grants the pharmaceutical giant…
Read More
Opdivo Secures Landmark US and EU Approvals for Classical Hodgkin Lymphoma Across Pediatric and Adult Populations
Bristol Myers Squibb’s (BMS) groundbreaking immunotherapy, Opdivo (nivolumab), has achieved a significant milestone with dual approvals from the U.S. Food…
Read MoreYOU MAY HAVE MISSED
